Navigation Links
Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
Date:4/7/2009

ROCKVILLE, Md., April 7 /PRNewswire/ -- Glycotex, Inc. today announced the completion of a scheduled interim analysis in a Phase II study evaluating the effect of investigational GLYC-101 gel on complete wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area.

The interim analysis was conducted after 26 subjects completed the study. The comparison of each active arm to placebo with respect to the primary endpoint (time to complete wound closure) shows positive results when considering the full dataset of patient data from all treatment combinations.

Specifically, the efficacy outcomes were statistically significantly different when comparing GLYC-101 0.1% and GLYC-101 1.0% groups to placebo (p values are 0.0062 and 0.0331, respectively). These interim results suggest that the time to wound closure will be shorter for eyelids treated on the active arms when compared to placebo in the final analysis. Assessment of safety data is ongoing.

This ongoing Phase II randomized, double-blind, placebo-controlled clinical study will continue enrolment to approximately 48 patients at one clinical trial site in Beverly Hills, California. Patients are randomized to receive either GLYC-101 0.1%, GLYC-101 1.0%, or placebo gel on one lower eyelid, and a different test article on the other lower eyelid applied topically to the laser-ablated area immediately following the laser procedure and for four consecutive days thereafter for a total of five applications. The primary efficacy endpoint of the study is time to complete wound healing, and the secondary efficacy point is cosmetic outcomes, including scarring. The study is observing the effects of the topical agent over the course of one month following the initial treatment with the investigational compound (GLYC-101 gel) or placebo.

About GLYC-101


'/>"/>
SOURCE Glycotex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014 Amgen (NASDAQ: ... Administration (FDA) has granted priority review designation for ivabradine ... is an oral drug that inhibits the I ... node, the body,s cardiac pacemaker. 1 Ivabradine works ... myocardial contractility or ventricular repolarization. 1 Heart failure ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... First U.S. Clinical Data on XIENCE V ... Follow-Up,Results from the ABSORB Bioabsorbable Stent Clinical ... /PRNewswire-FirstCall/ --,Abbott will present data from several ... during a number of late-breaking,clinical trial and ...
... La Jolla,Pharmaceutical Company today announced updated interim antibody,reduction ... (abetimus,sodium), its drug candidate for systemic lupus erythematosus,("lupus" ... that there is a definitive and significant dose ... mg doses of Riquent compared,with placebo (p=0.0001). These ...
Cached Medicine Technology:Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
(Date:8/28/2014)... 28, 2014 The next episode of ... from Tallahassee, Fla. He’s a drama coach who longs ... frame has made achieving that dream impossible. , Featuring ... Weight Loss” airs Tuesday, September 2 (9:00-11:00 p.m., ET/PT) ... wears a big smile on the outside to hide ...
(Date:8/27/2014)... The report provides market analysis of “Military ... Finder, LIDAR, 3D scanner, Laser Weapon, Dazzlers, Laser sights, ... Altimeter) by Domain (Aerospace, Defense and Homeland Security) - ... MarketsandMarkets, and its application in the aerospace and defense ... Systems market is expected to register a CAGR of ...
(Date:8/27/2014)... FL (PRWEB) August 27, 2014 ... money-saving dental plans, has launched in the state ... access to quality, affordable dental care services at ... destination for Tennessee consumers looking to save money ... dental rates as a member of discount fee ...
(Date:8/27/2014)... National Resident Matching Program International ... Medical Education in Europe (AMEE) Conference being held at ... – September 3, 2014. As an exhibitor, NRMPI ... community, share the benefits of its matching services, and ... in countries throughout the world. , “Exhibiting ...
(Date:8/27/2014)... Arrow, OK (PRWEB) August 27, 2014 When ... their guests a comfortable bed to sleep without breaking the ... the market for a new foam mattress set for the ... to sleep on, Bedding Mart has it all during their ... stock up on some of the best mattresses for the ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Rod’s Journey Begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 4Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 3Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Bedding Mart, Top Mattress Store in Broken Arrow Oklahoma, Announces a Huge Labor Day Sale 2
... accident, skull separating from her spine, has survived to tell ... ,A car crash slammed her into the dashboard. Her ... and other internal organs remained intact. The rare condition is ... no control over her head. ,Surgeons said her ...
... Since it is a very painful process, continuous attempts are ... the patient. ,Now researchers say that LHRH agonists ... the production of a female hormone that encourages some tumours ... often mimicking the action of a naturally occurring substance. ...
... affects to work, sleep and performance of other activities but ... and your concentration. ,This is the finding ... Rashiq at the University of Alberta. ,As a ... Pain Centre in Edmonton, Canada, the researchers studied 24 patients, ...
... a type of kidney malignancy called renal cancer according to ... Women's Hospital in Boston found that women and men who ... about 30 percent less likely to develop renal cell cancer ... drank beer, wine or liquor. ,Jung Eun Lee ...
... addition of folic acid to flour or bread mandatory in order ... ,After lengthy public consultations the Food Standards Agency (FSA) ... next month after it decides whether folic acid should be added ... the FSA's proposals, it will be the first time since the ...
... of Psychiatric and Mental Health Nursing in a recent report, ... health support to the victims of the 2005 Bali ... first explosions in 2002. ,Staff at the Royal ... recipients of vital personal support from mental health nurses. ...
Cached Medicine News:Health News:30-year-old Woman Survives 'internal Decapitation' 2Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3Health News:Bali Bombings Helped Improve Trauma Care 2Health News:Bali Bombings Helped Improve Trauma Care 3
... Most practitioners consider the HOPE nebulizer the ... have been made to put everything together in ... The result is our #11320 Adult HOPE Kit ... corrugated tubing and pediatric aerosol mask all in ...
... medication nebulizers offer a spill-proof design and ... a 45° angle. All medical nebulizers are ... variety of configurations are available., ,All ... ,Portex® medication nebulizers feature consistently fine ...
... delivery of medication as well as humidification, ... closed dilution, high volume, continuous medication nebulizer ... to patients. Its 200 ml reservoir and ... 8 hours of nebulized medication delivery at ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: